Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck.
Shares of both drugmakers fell even though the data, released in full later Thursday following the leak, appeared meaningful for patients and positive relative to Wall Street expectations.
The personalized vaccine, known as intismeran autogene, paired with Merck’s immunotherapy Keytruda reduced the risk of recurrence or death in certain melanoma patients by 42% compared with Keytruda alone.
The data also showed that the shot along with Keytruda reduced the risk of cancer spreading to distant parts of the body or death by 38%, compared with just the immunotherapy.
The companies said about 82% of patients who received the personalized cancer vaccine alongside Keytruda were alive without their melanoma returning at two years after receiving the shot, compared with 70% of those who received…
